Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $605.00 at Truist Financial

Intuitive Surgical (NASDAQ:ISRG) had its price target decreased by Truist Financial from $666.00 to $605.00 in a research report report published on Monday morning,Benzinga reports. Truist Financial currently has a buy rating on the medical equipment provider’s stock.

ISRG has been the subject of a number of other reports. Evercore ISI lifted their price target on Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $522.00 to $650.00 in a research note on Monday, December 2nd. Barclays lifted their price target on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, Raymond James raised their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $610.19.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $488.80 on Monday. The business has a 50-day moving average of $566.38 and a 200-day moving average of $531.96. The company has a market capitalization of $174.10 billion, a PE ratio of 76.26, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical has a 1-year low of $364.17 and a 1-year high of $616.00.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the completion of the sale, the chief financial officer now directly owns 2,630 shares in the company, valued at $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,754 shares of company stock worth $17,691,621. Company insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of institutional investors have recently added to or reduced their stakes in ISRG. Atala Financial Inc acquired a new stake in Intuitive Surgical in the fourth quarter worth approximately $25,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $26,000. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $28,000. Finally, Hurley Capital LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $28,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.